Jan van de Winkel, CEO of one of Europe’s leading biotech companies, Genmab, highlighted the need for Western pharma companies to embrace Chinese biotech innovation, despite growing anti-Chinese sentiment in the US. Following Genmab’s acquisition of US-Chinese drug maker ProfoundBio, van de Winkel noted the rapid growth of Chinese biotech’s supported by government funding, which has already attracted the attention of major companies – including AstraZeneca and GSK – who have also made significant deals in China.
For more, please find the original story source here.
